Trevi Therapeutics, Inc.
NASDAQ:TRVI
Overview | Financials
Company Name | Trevi Therapeutics, Inc. |
Symbol | TRVI |
Currency | USD |
Price | 4 |
Market Cap | 357,462,800 |
Dividend Yield | 0% |
52-week-range | 1.27 - 4.675 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Jennifer L. Good |
Website | https://www.trevitherapeutics.com |
An error occurred while fetching data.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD